Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free MCRB Stock Alerts

Seres Therapeutics (MCRB) Competitors

Seres Therapeutics logo
$7.50 -0.19 (-2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$7.42 -0.09 (-1.13%)
As of 06:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MCRB vs. AVXL, ABEO, ORGO, AMRN, and RZLT

Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Anavex Life Sciences (AVXL), Abeona Therapeutics (ABEO), Organogenesis (ORGO), Amarin (AMRN), and Rezolute (RZLT). These companies are all part of the "pharmaceutical products" industry.

How does Seres Therapeutics compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Anavex Life Sciences' return on equity of -38.76% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -38.76% -35.01%
Seres Therapeutics N/A -111.10%-32.28%

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 6 articles in the media. Anavex Life Sciences' average media sentiment score of 0.90 beat Seres Therapeutics' score of 0.29 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Seres Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anavex Life Sciences has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500.

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 534.92%. Seres Therapeutics has a consensus price target of $14.00, indicating a potential upside of 86.67%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Seres Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Seres Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$46.38M-$0.46N/A
Seres Therapeutics$789K91.56$5.70M$0.6611.36

31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Anavex Life Sciences beats Seres Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Seres Therapeutics compare to Abeona Therapeutics?

Abeona Therapeutics (NASDAQ:ABEO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Abeona Therapeutics has a beta of 1.35, indicating that its share price is 35% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.

In the previous week, Seres Therapeutics had 2 more articles in the media than Abeona Therapeutics. MarketBeat recorded 6 mentions for Seres Therapeutics and 4 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.74 beat Seres Therapeutics' score of 0.29 indicating that Abeona Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Seres Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Abeona Therapeutics' return on equity of -60.65% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona TherapeuticsN/A -60.65% -40.78%
Seres Therapeutics N/A -111.10%-32.28%

Abeona Therapeutics has higher revenue and earnings than Seres Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$5.82M56.98$71.18M$1.035.66
Seres Therapeutics$789K91.56$5.70M$0.6611.36

Abeona Therapeutics presently has a consensus price target of $19.00, indicating a potential upside of 225.90%. Seres Therapeutics has a consensus price target of $14.00, indicating a potential upside of 86.67%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Seres Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Abeona Therapeutics beats Seres Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.

Organogenesis has a net margin of 5.32% compared to Seres Therapeutics' net margin of 0.00%. Organogenesis' return on equity of 21.41% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis5.32% 21.41% 10.84%
Seres Therapeutics N/A -111.10%-32.28%

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 33.0% of Organogenesis shares are held by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Organogenesis has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500.

Organogenesis presently has a consensus price target of $8.50, indicating a potential upside of 228.19%. Seres Therapeutics has a consensus price target of $14.00, indicating a potential upside of 86.67%. Given Organogenesis' stronger consensus rating and higher probable upside, research analysts clearly believe Organogenesis is more favorable than Seres Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Organogenesis has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$563.03M0.59$37.03M$0.0832.38
Seres Therapeutics$789K91.56$5.70M$0.6611.36

In the previous week, Seres Therapeutics had 3 more articles in the media than Organogenesis. MarketBeat recorded 6 mentions for Seres Therapeutics and 3 mentions for Organogenesis. Organogenesis' average media sentiment score of 0.50 beat Seres Therapeutics' score of 0.29 indicating that Organogenesis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Seres Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Organogenesis beats Seres Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Amarin?

Seres Therapeutics (NASDAQ:MCRB) and Amarin (NASDAQ:AMRN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Seres Therapeutics has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$789K91.56$5.70M$0.6611.36
Amarin$216.76M1.39-$38.80M-$0.65N/A

In the previous week, Amarin had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 9 mentions for Amarin and 6 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.29 beat Amarin's score of 0.17 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Amarin
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Seres Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the S&P 500. Comparatively, Amarin has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500.

Seres Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -111.10% -32.28%
Amarin -15.51%-2.99%-2.07%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 4.7% of Seres Therapeutics shares are owned by insiders. Comparatively, 4.2% of Amarin shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Seres Therapeutics presently has a consensus price target of $14.00, suggesting a potential upside of 86.67%. Amarin has a consensus price target of $12.00, suggesting a potential downside of 17.24%. Given Seres Therapeutics' higher probable upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Amarin
2 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00

Summary

Seres Therapeutics beats Amarin on 10 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Rezolute?

Seres Therapeutics (NASDAQ:MCRB) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Seres Therapeutics has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$789K91.56$5.70M$0.6611.36
RezoluteN/AN/A-$74.41M-$0.93N/A

In the previous week, Seres Therapeutics had 3 more articles in the media than Rezolute. MarketBeat recorded 6 mentions for Seres Therapeutics and 3 mentions for Rezolute. Seres Therapeutics' average media sentiment score of 0.29 beat Rezolute's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Seres Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rezolute
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Seres Therapeutics has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Rezolute's return on equity of -64.81% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Seres TherapeuticsN/A -111.10% -32.28%
Rezolute N/A -64.81%-59.37%

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 14.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 86.67%. Rezolute has a consensus price target of $8.00, suggesting a potential upside of 143.16%. Given Rezolute's stronger consensus rating and higher possible upside, analysts clearly believe Rezolute is more favorable than Seres Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Seres Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Rezolute
1 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.45

Summary

Seres Therapeutics and Rezolute tied by winning 7 of the 14 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MCRB vs. The Competition

Export
MetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$72.24M$3.40B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio11.3638.8529.0428.48
Price / Sales91.56155.54476.4860.89
Price / Cash7.0057.8827.6236.52
Price / Book1.537.039.676.67
Net Income$5.70M$23.62M$3.55B$332.64M
7 Day Performance5.78%3.67%1.70%2.01%
1 Month Performance-19.09%7.17%5.62%9.19%
1 Year Performance-18.74%67.04%34.42%39.59%

Seres Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MCRB
Seres Therapeutics
2.2519 of 5 stars		$7.50
-2.5%		$14.00
+86.7%		N/A$72.24M$789K11.36330
AVXL
Anavex Life Sciences
2.3118 of 5 stars		$3.29
-1.5%		$22.00
+568.7%		N/A$309.52MN/AN/A40
ABEO
Abeona Therapeutics
2.7471 of 5 stars		$5.34
-0.9%		$19.00
+255.8%		N/A$306.60M$5.82M5.1890
ORGO
Organogenesis
3.7204 of 5 stars		$2.39
+1.7%		$8.50
+255.6%		N/A$302.31M$564.17M29.88950
AMRN
Amarin
1.1916 of 5 stars		$13.93
-2.7%		$12.00
-13.9%		N/A$297.70M$213.65MN/A360

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel